# Planning and Evaluation

> **NIH NIH P30** · H. LEE MOFFITT CANCER CTR & RES INST · 2020 · $69,122

## Abstract

Planning & Evaluation 
PROJECT SUMMARY 
Dr. Thomas Sellers utilizes internal and external advisory groups to facilitate strategic planning, monitoring, 
and evaluation of Moffitt Cancer Center (MCC) cancer research activities. These processes have been critical 
to development of Moffitt 3.0 and the Research Strategic Plan (RSP). The goals of Planning & Evaluation are 
to: 1) develop, implement, and review a dynamic strategic plan; 2) utilize external experts to evaluate progress 
and future research priorities; and 3) operate an effective planning and evaluation infrastructure that enhances 
efficiency and stimulates collaboration, innovation, and strategic growth. 
Internal and external advisory groups provide guidance and recommendations. The Research Executive 
Committee (REX, which functions as the CCSG Senior Leadership) is comprised of the Center Director and 
the six Associate Center Directors (ACDs) and is the primary decision-making group of the Center. REX led 
development of the RSP, with the vision “to be the leader in understanding the complexity of cancer through 
team science and applying those insights for human benefit.” Progress in achieving the RSP is reviewed by 
REX and the groups described below. 
External planning and evaluation utilizes annual meetings of the External Advisory Committee (EAC), 
supplemented by focused external reviews (e.g., external shared resource consultants and clinical research 
advisors). The Scientific Leadership Committee (SLC) at MCC functions similarly to a traditional executive 
committee at other centers; membership includes REX, research program leaders, and Center of Excellence 
directors. The SLC provides primary review of programs, shared resources, and clinical trials and includes four 
standing subcommittees, each chaired by a different ACD: 1) Membership Committee (MC, review of new 
and ongoing members for cancer focus and scientific productivity); 2) Core Leadership Committee (CLC, 
shared resource reviews, chargebacks, assessment of member needs); 3) Clinical Research Action 
Committee (CRAC, clinical research standards and trial portfolio); and 4) Innovation & Technology 
Committee (ITC, new technologies and tools). 
In addition, MCC supports seminars and retreats at the program, division (basic, clinical, and population 
science) and center-wide levels to ensure full membership engagement in planning and evaluation. An annual 
scientific symposium and Business of Biotech events bring together members, staff, and external collaborators 
to develop the collaborative research central to CCSG Programs.

## Key facts

- **NIH application ID:** 9868903
- **Project number:** 5P30CA076292-22
- **Recipient organization:** H. LEE MOFFITT CANCER CTR & RES INST
- **Principal Investigator:** John L. Cleveland
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $69,122
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9868903

## Citation

> US National Institutes of Health, RePORTER application 9868903, Planning and Evaluation (5P30CA076292-22). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9868903. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*